Glioblastoma Clinical Trial
Official title:
A Phase I/II Study of the Safety and Feasibility of Administering T Cells Expressing Anti-EGFRvIII Chimeric Antigen Receptor to Patients With Malignant Gliomas Expressing EGFRvIII
Background:
The National Cancer Institute (NCI) Surgery Branch has developed an experimental therapy for
treating patients with gliomas that involves taking white blood cells from the patient,
growing them in the laboratory in large numbers, genetically modifying these specific cells
with a type of virus (retrovirus) to attack only the tumor cells, and then giving the cells
back to the patient. This type of therapy is called gene transfer. In this protocol, we are
modifying the patient's white blood cells with a retrovirus that has the gene for epidermal
growth factor receptor (EGFR) vIII incorporated in the retrovirus.
Objective:
The purpose of this study is to determine a safe number of these cells to infuse and to see
if these particular tumor-fighting cells (anti-EGFRvIII cells) are a safe and effective
treatment for advanced gliomas.
Eligibility:
- Adults age 18-70 with malignant glioma expressing the EGFRvIII molecule.
Design:
Work up stage: Patients will be seen as an outpatient at the National Institutes of Health
(NIH) clinical Center and undergo a history and physical examination, scans, x-rays, lab
tests, and other tests as needed
Leukapheresis: If the patients meet all of the requirements for the study they will undergo
leukapheresis to obtain white blood cells to make the anti-EGFRvIII cells. {Leukapheresis is
a common procedure, which removes only the white blood cells from the patient.}
Treatment: Once their cells have grown, the patients will be admitted to the hospital for the
conditioning chemotherapy, the anti-EGFRvIII cells, and aldesleukin. They will stay in the
hospital for about 4 weeks for the treatment.
Follow up: Patients will return to the clinic for a physical exam, review of side effects,
lab tests, and scans every month for the first year, and then every 1-2 months as long as
their tumors are shrinking. Follow up visits will take up to 2 days.
BACKGROUND:
- Patients with recurrent gliomas have very limited treatment options. Epidermal growth
factor receptor (EGFR).
(EGFRvIII) is the most common mutant variant of EGFR and is present in 24-67% of patients
with glioblastoma.
- EGFRvIII expression promotes oncogenesis and is associated with poor prognosis.
- EGFRvIII is not expressed in normal tissue and is an attractive target for
immunotherapy.
- We have constructed a retroviral vector that contains a chimeric antigen receptor (CAR)
that recognizes the EGFRvIII tumor antigen, which can be used to mediate genetic
transfer of this CAR with high efficiency without the need to perform any selection.
OBJECTIVES:
Primary Objectives
- To evaluate the safety of the administration of anti-EGFRvIII CAR engineered peripheral
blood lymphocytes in patients receiving the non-myeloablative, lymphodepleting
preparative regimen and aldesleukin.
- Determine the six month progression free survival of patients receiving anti-EGFRvIII
CAR-engineered peripheral blood lymphocytes and aldesleukin following a
nonmyeloablative, lymphodepleting preparative regimen.
ELIGIBILITY:
- Histologically proven glioblastoma or gliosarcoma expressing EGFRvIII as determined by
immunohistochemistry (IHC) or Reverse transcription polymerase chain reaction (RT-PCR)
- Failed prior standard treatment with radiotherapy with or without chemotherapy
- Karnofsky performance score (KPS) greater than or equal to 60
- Cardiac, pulmonary and laboratory parameters within acceptable limits
DESIGN:
- The study will be conducted using a Phase I/II design.
- Patients will receive a non-myeloablative, lymphodepleting preparative regimen
consisting of cyclophosphamide and fludarabine followed by intravenous infusion of ex
vivo tumorreactive, CAR gene-transduced peripheral blood mononuclear cells (PBMC), plus
intravenous (IV) aldesleukin.
- Once the maximum tolerated cell dose (MTD) has been determined, the study will proceed
to the phase II portion.
- In the phase II portion of the trial, patients will be accrued to two cohorts:
- Patients with recurrent malignant glioma receiving steroids at the time of
treatment.
- Patients with recurrent malignant glioma not receiving steroids at the time of
treatment.
- A total of 107 patients may be enrolled over a period of 7 years.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05664243 -
A Phase 1b / 2 Drug Resistant Immunotherapy With Activated, Gene Modified Allogeneic or Autologous γδ T Cells (DeltEx) in Combination With Maintenance Temozolomide in Subjects With Recurrent or Newly Diagnosed Glioblastoma
|
Phase 1/Phase 2 | |
| Completed |
NCT02768389 -
Feasibility Trial of the Modified Atkins Diet and Bevacizumab for Recurrent Glioblastoma
|
Early Phase 1 | |
| Recruiting |
NCT05635734 -
Azeliragon and Chemoradiotherapy in Newly Diagnosed Glioblastoma
|
Phase 1/Phase 2 | |
| Completed |
NCT03679754 -
Evaluation of Ad-RTS-hIL-12 + Veledimex in Subjects With Recurrent or Progressive Glioblastoma, a Substudy to ATI001-102
|
Phase 1 | |
| Completed |
NCT01250470 -
Vaccine Therapy and Sargramostim in Treating Patients With Malignant Glioma
|
Phase 1 | |
| Terminated |
NCT03927222 -
Immunotherapy Targeted Against Cytomegalovirus in Patients With Newly-Diagnosed WHO Grade IV Unmethylated Glioma
|
Phase 2 | |
| Recruiting |
NCT03897491 -
PD L 506 for Stereotactic Interstitial Photodynamic Therapy of Newly Diagnosed Supratentorial IDH Wild-type Glioblastoma
|
Phase 2 | |
| Active, not recruiting |
NCT03587038 -
OKN-007 in Combination With Adjuvant Temozolomide Chemoradiotherapy for Newly Diagnosed Glioblastoma
|
Phase 1 | |
| Completed |
NCT01922076 -
Adavosertib and Local Radiation Therapy in Treating Children With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas
|
Phase 1 | |
| Recruiting |
NCT04391062 -
Dose Finding for Intraoperative Photodynamic Therapy of Glioblastoma
|
Phase 2 | |
| Active, not recruiting |
NCT03661723 -
Pembrolizumab and Reirradiation in Bevacizumab Naïve and Bevacizumab Resistant Recurrent Glioblastoma
|
Phase 2 | |
| Active, not recruiting |
NCT02655601 -
Trial of Newly Diagnosed High Grade Glioma Treated With Concurrent Radiation Therapy, Temozolomide and BMX-001
|
Phase 2 | |
| Completed |
NCT02206230 -
Trial of Hypofractionated Radiation Therapy for Glioblastoma
|
Phase 2 | |
| Completed |
NCT03493932 -
Cytokine Microdialysis for Real-Time Immune Monitoring in Glioblastoma Patients Undergoing Checkpoint Blockade
|
Phase 1 | |
| Terminated |
NCT02709889 -
Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06058988 -
Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer
|
Phase 2 | |
| Completed |
NCT03018288 -
Radiation Therapy Plus Temozolomide and Pembrolizumab With and Without HSPPC-96 in Newly Diagnosed Glioblastoma (GBM)
|
Phase 2 | |
| Withdrawn |
NCT03980249 -
Anti-Cancer Effects of Carvedilol With Standard Treatment in Glioblastoma and Response of Peripheral Glioma Circulating Tumor Cells
|
Early Phase 1 | |
| Not yet recruiting |
NCT04552977 -
A Trail of Fluzoparil in Combination With Temozolomide in Patients With Recurrent Glioblastoma
|
Phase 2 | |
| Withdrawn |
NCT02876003 -
Efficacy and Safety of G-202 in PSMA-Positive Glioblastoma
|
Phase 2 |